Decera Clinical Insights

AI is rapidly reshaping cancer care, but where do we draw the line? in this episode of Oncology Unscripted, @marshalj23 explores both the promise and the pressure of AI in oncology, from predicting treatment responses and supporting clinical trials to raising deeper questions about compassion, bias, and accountability. As AI continues to evolve, one thing becomes clear: access to information is expanding, but interpretation and human connection remain critical. The future of oncology won’t be defined by AI alone, but by how clinicians choose to use it. 🔗 Watch the full episode: bit.ly/4kcAhlI #Oncology #AIinHealthcare #CancerCare #MedicalEducation #EvidenceToAction

You’re invited to join us and a select group of peers for an in-person Dinner & Discussion on MDS-associated anemia. Hear from Bart Scott, MD, and engage in a case-based conversation focused on evolving treatment strategies for patients with lower-risk MDS. 📅 May 8, 2026 🕒 6:30–8:30 PM AKT 📍 Anchorage, AK This is a consulting opportunity, and space is limited and intended for actively treating clinicians. 👉 Register now: bit.ly/3QG5T8D

Join Michael Morse, MD to gain insights on the first-in-class targeted inhibitor of mIDH1 in previously treated, locally advanced or metastatic Cholangiocarcinoma (CCA). Sign up for this 45-minute webinar today! deceraclinical.com/insights/event… #Oncology

Catch up on the latest Oncology Unscripted episodes with @marshalj23 🍃 New conversations are now live, exploring global shifts in cancer care leadership, the growing economic burden of cancer, emerging insights into CRC in younger populations, and what every clinician should communicate to newly diagnosed patients. Watch the newest episodes here 👉 bit.ly/4kcAhlI #Oncology #CancerCare #GICancer #OncologyInsights

Cancer doesn’t evolve slowly anymore. After a trip to the Galápagos, @marshalj23 draws a powerful parallel between natural selection and what we’re seeing in oncology today. As treatments advance, cancer adapts, often faster than we expect. And while AI and precision medicine are reshaping care, they’re also raising an important question: What role does the physician play in a rapidly evolving, tech-driven future? The answer isn’t either/or. It’s progress and perspective, using innovation to move forward without losing the human touch. 👉 Watch here: bit.ly/4kcAhlI

What does leadership in oncology really look like over time? Sometimes, it’s believing in something long before the field catches up. In this episode of Oncology Unscripted, Dr. John Marshall and Dr. Louis Weiner reflect on the early days of immunotherapy, when the idea of using the immune system to treat cancer was met with skepticism, and what it means to stay committed to a vision despite doubt. From shaping the growth of cancer immunology as a field to seeing the real-world impact of that work in patients’ lives, this conversation is a powerful reminder that progress in oncology is built on persistence, curiosity, and long-term thinking. Watch the full discussion: bit.ly/4kcAhlI #OncologyInsights

Standing in the Galápagos, it’s hard not to think about evolution and how it applies to oncology. In this episode of Oncology Unscripted, Dr. John Marshall connects insights from a recent cholangiocarcinoma study to the broader, global evolution of cancer research, asking what it means for the future of care and leadership in oncology. Watch the full discussion: bit.ly/4kcAhlI #OncologyUnscripted #EvolutioninOncology

Leadership in oncology is constantly evolving, shaped by scientific breakthroughs, institutional change, and the people driving progress forward. In The Evolution of Leadership: A Candid Conversation With Dr. Louis Weiner, Dr. @marshalj23 sits down with Dr. Weiner to reflect on the future of cancer research, the realities of leading through change, and the vision required to push innovation forward, even when others may not yet see it. From early skepticism around harnessing the immune system to treat cancer to the transformative impact of immunotherapy today, this conversation highlights what it truly means to lead with conviction in oncology. Watch the full discussion: bit.ly/4q4zTa9 #ClinicalInsights #Oncology

Treatment strategies in relapsed/refractory multiple myeloma continue to evolve as novel mechanisms of action reshape later-line care. Join Integrating Novel Mechanisms in Relapsed/Refractory Multiple Myeloma, a virtual program exploring the current treatment landscape, key clinical data, and practical considerations for integrating emerging therapies into clinical practice. The session will also address sequencing decisions, tolerability management, and approaches to optimizing patient outcomes in complex care settings. 📅 April 8 | 💻 Virtual | 👉 Learn more: bit.ly/4t2lBcF #ClinicalInsights #Oncology

What’s actually happening at the FDA right now? In this Oncology Unscripted clip, Dr. John Marshall (@marshalj23) breaks down growing instability at the agency—including staffing reductions, leadership turnover, hiring freezes, and a planned structural reorganization. Since April 2025, roughly 3,500 FDA jobs have been eliminated, raising concerns across the oncology community about how these changes could affect the pace of innovation and access to new cancer therapies. ▶️ Watch the discussion: bit.ly/4bbEbqY #OncologyUnscripted #CancerCare #FDA #Oncology

Treatment strategies for squamous cell carcinoma of the anal canal continue to evolve as new clinical evidence and guideline updates shape care for patients with advanced disease. Join this expert-led virtual program exploring SCAC epidemiology and risk factors, key clinical trial findings, and important safety considerations that influence treatment decision-making in inoperable locally recurrent or metastatic settings. Access to timely oncology education helps clinicians stay aligned with emerging data and supports more confident, personalized approaches to patient care. 👉 Learn more: bit.ly/3PIUzIc 📅 March 25, 2026 ⏰ 12:15–12:45 PM ET 💻 Virtual #Oncology #CancerCare #ClinicalResearch

What happens to cancer care when instability hits the systems that support drug development and approval? In this MedBuzz segment of Oncology Unscripted, Dr. @marshalj23 discusses growing uncertainty at the FDA, from job cuts to leadership turnover and structural changes, and what it could mean for the future of oncology innovation. “We could be in for some trouble ahead… but we need to talk about it and make it better than it was before.” Watch the full episode: bit.ly/4bbEbqY

Managing thrombotic risk in polycythemia vera requires careful assessment and timely clinical decision-making. This program reviews how to: ✅ Assess Hct levels and WBC counts ✅ Evaluate overall thrombotic risk ✅ Consider treatment strategies in PV ✅ Discuss potential patient outcomes Explore the program: bit.ly/4uesCYG #PolycythemiaVera #Hematology #MPN #ClinicalEducation

$25 trillion. That’s the projected global cost of cancer care over the next 30 years. Let that sink in. At the same time, many patients around the world still don’t have access to basic cancer care. So where does that $25 trillion go? Is it expanding access to underserved populations? Or is it driven by increasingly complex, high-cost therapies and consumables? In this episode of #OncologyUnscripted, @marshalj23 explores the financial future of cancer care against a backdrop of rising incidence, falling mortality, and political uncertainty in Washington, DC. Cancer outcomes are improving. Costs are escalating. Access remains uneven. How do we reconcile all three? 👉 Watch the full episode and join the conversation: deceraclinical.com/insights/activ…

In the latest episode of Oncology Unscripted, we unpack a paradox shaping cancer care today: 📈 Cancer incidence is rising, breast cancer, prostate cancer, young-onset colon cancer, melanoma in women. 📉 Yet cancer mortality has fallen by more than 30% over time. 💰 Meanwhile, global cancer care costs are projected to reach $25 trillion. Each year, hundreds of thousands of lives are still lost. That sounds devastating, and it is. But it also reflects progress. More patients are being diagnosed. More patients are being cured. The question is no longer just can we treat cancer? It’s how do we sustain innovation, access, and funding in an era of political uncertainty and research slowdowns? 👏 Watch this episode of #OncologyUnscripted as we explore where we are, what’s at stake, and how we move forward: bit.ly/4b02Iza

What if improving outcomes starts with what’s happening inside the gut? In this #OncologyUnscripted conversation, @marshalj23 reflects on emerging data linking the microbiome to early-onset colon cancer risk and survival, including findings showing improved colon cancer mortality among patients taking GLP-1 receptor agonists. The discussion explores how our interaction with the microbiome may influence not only cancer outcomes, but health across a wide range of diseases. Catch this high-level insight, and more perspectives you may have missed, on the latest episode: bit.ly/3ZVLDkx

Fiber isn’t about restriction, it’s about feeding the right ecosystem 🌱 Robynne Chutkan, MD breaks down why unprocessed plant fiber fuels gut microbes, drives short-chain fatty acid production, and helps keep the immune system in balance. No shortcuts, no supplements, it starts with what we eat. Watch the full #OncologyUnscripted episode with @marshalj23 to go deeper into the gut–microbiome connection and patient care: bit.ly/3O3BnnJ

Why are more young adults being diagnosed with #colorectalcancer? In this Oncology Unscripted episode, @marshalj23 digs into emerging research on bacteria-produced mutagens like colibactin, their link to early-onset CRC, and what new data on GLP-1 receptor agonists may mean for colon cancer mortality. Watch the full conversation and explore what’s changing in CRC risk and outcomes: bit.ly/3ZVLDkx #ColonCancer #OncologyInsights #CancerResearch

How much does the gut really influence modern disease? ✨ In this #OncologyUnscripted conversation, @marshalj23 sits down with Dr Robynne Chutkan to unpack the microbiome, the impact of the modern diet, and why deeper understanding of gut health is becoming essential to patient care. Watch the full interview and rethink the gut story: bit.ly/3O3BnnJ

Tune in to an expert-led virtual broadcast on February 18th at 12:15 PM (ET) exploring a targeted treatment option for adults with previously treated, unresectable, locally advanced, or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement. 👉 This session will review molecular profiling for patient identification, mechanism of action, clinical trial design, efficacy and safety findings, and long-term follow-up data, along with dosing considerations and patient support resources: bit.ly/46u83Nt